Skip to content

CNBX PHARMACEUTICALS INC.: 10-Q filed 2024-07-15

What CNBX PHARMACEUTICALS INC. reported in its quarterly report filed 2024-07-15 (fiscal Q3 2025): 28 published measures, 86 facts as tagged in accession 0001683168-24-004831.

This filing

Form
10-Q (quarterly report)
Filed
2024-07-15
Fiscal period
fiscal Q3 2025
Accession
0001683168-24-004831 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All CNBX PHARMACEUTICALS INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2024-05-3180,027USD
At 2023-08-31499,039USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2024-05-31-2,454,371USD
At 2024-02-29-2,358,534USD
At 2023-08-31-2,017,289USD
At 2023-05-31-1,909,442USD
At 2023-02-28-2,011,531USD
At 2022-08-31-1,632,311USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2024-05-3173,406USD
At 2023-08-31129,696USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2024-03-01 to 2024-05-31-130,632USD92
2023-09-01 to 2024-05-31-634,614USD274
2023-03-01 to 2023-05-31-154,690USD92
2022-09-01 to 2023-05-31-3,136,680USD273

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2023-09-01 to 2024-05-31-196,019USD274
2022-09-01 to 2023-05-31-133,038USD273

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

PeriodValueUnitDays
2024-03-01 to 2024-05-310USD92
2023-09-01 to 2024-05-31130,074USD274
2023-03-01 to 2023-05-31310,165USD92
2022-09-01 to 2023-05-31310,165USD273

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2023-09-01 to 2024-05-3126,252USD274
2022-09-01 to 2023-05-3134,972USD273

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2023-09-01 to 2024-05-31113,477USD274
2022-09-01 to 2023-05-3124,702USD273

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2024-05-31-24,893,816USD
At 2023-08-31-24,259,202USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2024-03-01 to 2024-05-3131,111,352shares92
2023-09-01 to 2024-05-3129,964,272shares274
2023-03-01 to 2023-05-319,265,865shares92
2022-09-01 to 2023-05-314,030,048shares273

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2024-03-01 to 2024-05-3131,111,352shares92
2023-09-01 to 2024-05-3129,964,272shares274
2023-03-01 to 2023-05-319,265,865shares92
2022-09-01 to 2023-05-314,030,048shares273

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2024-03-01 to 2024-05-310USD/shares92
2023-09-01 to 2024-05-31-0.02USD/shares274
2023-03-01 to 2023-05-31-0.02USD/shares92
2022-09-01 to 2023-05-31-0.78USD/shares273

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

PeriodValueUnitDays
2024-03-01 to 2024-05-310USD/shares92
2023-09-01 to 2024-05-31-0.02USD/shares274
2023-03-01 to 2023-05-31-0.02USD/shares92
2022-09-01 to 2023-05-31-0.78USD/shares273

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2024-05-310USD
At 2023-08-31274,731USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2023-09-01 to 2024-05-31104,745USD274
2022-09-01 to 2023-05-31145,505USD273

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2024-03-01 to 2024-05-31-152,278USD92
2023-09-01 to 2024-05-31-530,606USD274
2023-03-01 to 2023-05-31-173,082USD92
2022-09-01 to 2023-05-31-769,881USD273

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2024-05-3180,027USD
At 2023-08-31224,308USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2024-05-312,534,398USD
At 2023-08-312,516,328USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2024-03-01 to 2024-05-31152,278USD92
2023-09-01 to 2024-05-31660,680USD274
2023-03-01 to 2023-05-31483,247USD92
2022-09-01 to 2023-05-311,080,046USD273

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2024-03-01 to 2024-05-3142,884USD92
2023-09-01 to 2024-05-31268,722USD274
2023-03-01 to 2023-05-31263,115USD92
2022-09-01 to 2023-05-31338,330USD273

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2024-05-313,111,352shares
At 2023-08-3122,611,352shares

Cash including restricted cash

Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.

PeriodValueUnitDays
At 2024-05-3173,406USD
At 2023-08-31129,696USD
At 2023-05-3144,151USD
At 2022-08-31117,515USD

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2024-05-3122,436,334USD
At 2023-08-3122,239,652USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2024-05-316,621USD
At 2023-08-3194,612USD

Comprehensive income or loss

Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.

PeriodValueUnitDays
2024-03-01 to 2024-05-31-130,632USD92
2023-09-01 to 2024-05-31-634,614USD274
2023-03-01 to 2023-05-31-154,690USD92
2022-09-01 to 2023-05-31-3,196,550USD273

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2024-03-01 to 2024-05-31109,394USD92
2023-09-01 to 2024-05-31391,958USD274
2023-03-01 to 2023-05-31220,132USD92
2022-09-01 to 2023-05-31741,716USD273

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

PeriodValueUnitDays
2023-09-01 to 2024-05-3172,320USD274
2022-09-01 to 2023-05-31123,569USD273

Other nonoperating income or expense

Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.

PeriodValueUnitDays
2024-03-01 to 2024-05-3121,646USD92
2023-09-01 to 2024-05-31-15,074USD274
2023-03-01 to 2023-05-3118,392USD92
2022-09-01 to 2023-05-3128,499USD273

Inspect the source

Entity
CNBX PHARMACEUTICALS INC. / CIK 0001343009
Captured
SEC response SHA-256
915b78bb9f3d1ecdaff39577a9e5db4b6d0b32a87b795bd1dd92ab6d7b14ac19

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001343009.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))